Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
文献类型：期刊论文
| 作者 | Chen, Shulun1,2,3; Song, Zilan1,2,3; Zhang, Ao1,2,3
|
| 刊名 | CURRENT TOPICS IN MEDICINAL CHEMISTRY
 |
| 出版日期 | 2019 |
| 卷号 | 19期号:3页码:180-185 |
| ISSN号 | 1568-0266 |
| DOI | 10.2174/1568026619666190308131805 |
| 通讯作者 | Zhang, Ao(aozhang@simm.ac.cn) |
| 英文摘要 | Oncology immunotherapy has gained significant advances in recent years and benefits cancer patients with superior efficacy and superior clinical responses. Currently over ten immune checkpoint antibodies targeting CTLA-4 and PD-1/PD-L1 have received regulatory approval worldwide and over thousands are under active clinical trials. However, compared to the rapid advance of Monoclonal Antibody (mAb), studies on immunotherapeutic small molecules have far lagged behind. Small molecule immunotherapy not only can target immunosuppressive mechanisms similar to mAbs, but also can stimulate intracellular pathways downstream of checkpoint proteins in innate or adaptive immune cells that mAbs are unable to access. Therefore, small molecule immunotherapy can provide an alternative treatment modality either alone or complementary to or synergistic with extracellular checkpoint mAbs to address low clinical response and drug resistance. Fortunately, remarkable progress has achieved recently in the pursuit of small molecule immunotherapy. This review intends to provide a timely highlight on those clinically investigated small molecules targeting PD-1/PD-L1, IDO1, and STING. The most advanced IDO1 inhibitor epacadostat have been aggressively progressed into multiple clinical testings. Small molecule PD-1/PD-L1 inhibitors and STING activators are still in a premature state and their decisive application needs to wait for the ongoing clinical outcomes. Since no small molecule immunotherapy has been approved yet, the future research should continue to focus on discovery of novel small molecules with distinct chemo-types and higher potency, identification of biomarkers to precisely stratify patients, as well as validation of many other immune-therapeutic targets, such as LAG3, KIRs, TIM-3, VISTA, B7-H3, and TIGIT. |
| WOS关键词 | PEMBROLIZUMAB |
| 资助项目 | Chinese NSF[81773565] ; National Program on Key Basic Research Project of China[2015CB910603-004] ; Key Program of the Frontier Science of the Chinese Academy of Sciences[160621] ; Shanghai Commission of Science and Technology[16XD1404600] ; Strategic Leading Project A on Precision Medicine of the Chinese Academy of Sciences[XDA12020366] ; Strategic Leading Project A on Precision Medicine of the Chinese Academy of Sciences[XDA12020226] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000464102200003 |
| 出版者 | BENTHAM SCIENCE PUBL LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/290094]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Zhang, Ao |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Chinese Acad Sci, SIMM, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, SIMM, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Shulun,Song, Zilan,Zhang, Ao. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY,2019,19(3):180-185. |
| APA | Chen, Shulun,Song, Zilan,&Zhang, Ao.(2019).Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.CURRENT TOPICS IN MEDICINAL CHEMISTRY,19(3),180-185. |
| MLA | Chen, Shulun,et al."Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions".CURRENT TOPICS IN MEDICINAL CHEMISTRY 19.3(2019):180-185. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。